



**HAL**  
open science

## **A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study**

Derk Frank, Eric Durand, Sandra Lauck, Douglas F Muir, Mark Spence, Mariuca Vasa-Nicotera, David Wood, Francesco Saia, Cristóbal A Urbano-Carrillo, Damien Bouchayer, et al.

### ► To cite this version:

Derk Frank, Eric Durand, Sandra Lauck, Douglas F Muir, Mark Spence, et al.. A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study. *European Heart Journal*, 2024, pp.ehae147. 10.1093/eurheartj/ehae147 . hal-04534032

**HAL Id: hal-04534032**

**<https://hal.science/hal-04534032>**

Submitted on 5 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study

Derk Frank <sup>1,2\*</sup>, Eric Durand <sup>3</sup>, Sandra Lauck <sup>4</sup>, Douglas F. Muir <sup>5</sup>, Mark Spence<sup>6</sup>, Mariuca Vasa-Nicotera<sup>7</sup>, David Wood<sup>4</sup>, Francesco Saia <sup>8</sup>, Cristóbal A. Urbano-Carrillo <sup>9</sup>, Damien Bouchayer<sup>10</sup>, Vlad Anton Ilescu <sup>11</sup>, Christophe Saint Etienne<sup>12</sup>, Florence Leclercq <sup>13</sup>, Vincent Auffret <sup>14</sup>, Lluís Asmarats <sup>15,16</sup>, Carlo Di Mario <sup>17</sup>, Aurelie Veugeois<sup>18</sup>, Jiri Maly <sup>19</sup>, Andreas Schober <sup>20,21</sup>, Luis Nombela-Franco <sup>22</sup>, Nikos Werner<sup>23</sup>, Joan Antoni Gómez-Hospital <sup>24</sup>, Julia Mascherbauer <sup>25</sup>, Giuseppe Musumeci <sup>26</sup>, Nicolas Meneveau <sup>27</sup>, Thibaud Meurice<sup>28</sup>, Felix Mahfoud <sup>29</sup>, Federico De Marco <sup>30</sup>, Tim Seidler <sup>31,32,33</sup>, Florian Leuschner <sup>34</sup>, Patrick Joly<sup>35</sup>, Jean-Philippe Collet <sup>36†</sup>, Ferdinand Vogt <sup>37</sup>, Emilio Di Lorenzo<sup>38</sup>, Elmar Kuhn <sup>39</sup>, Vicente Peral Disdier <sup>40</sup>, Violetta Hachaturyan <sup>41</sup>, Claudia M. Lüske <sup>41</sup>, Radka Rakova <sup>42</sup>, Wilbert Wesselink <sup>42</sup>, Jana Kurucova <sup>42</sup>, Peter Bramlage <sup>41</sup>, and Gemma McCalmont <sup>5,43</sup>; for the BENCHMARK Investigator Group

<sup>1</sup>Department of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), University Clinical Centre Schleswig-Holstein (UKSH), Arnold-Heller Strasse 3, Haus K3, Kiel 24105, Germany; <sup>2</sup>Department of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), German Centre for Cardiovascular Research, partner site Hamburg/Kiel/Lübeck, Arnold-Heller Strasse 3, Haus K3, Kiel 24105, Germany; <sup>3</sup>Department of Cardiology, Univ Rouen Normandie, Inserm U1096, CHU Rouen, Rouen, France; <sup>4</sup>Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, BC, Canada; <sup>5</sup>Cardiology Department, James Cook University Hospital, Middlesbrough, UK; <sup>6</sup>Cardiology Department, Mater Private Network, Dublin, Ireland; <sup>7</sup>Cardiology Department, Hospital Sindelfingen-Böblingen, Sindelfingen, Germany; <sup>8</sup>Department of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy; <sup>9</sup>Cardiology Department, Hospital Regional Universitario de Málaga, Málaga, Spain; <sup>10</sup>Department of Cardiology, The Clinique de l'Infirmier Protestant, Lyon, France; <sup>11</sup>Department of Cardiology, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; <sup>12</sup>Department of Cardiology, Centre Hospitalier Régional Universitaire (CHRU) de Tours, Hôpital Trousseau, Tours, France; <sup>13</sup>Cardiology Department, Montpellier University Hospital, Montpellier University, Montpellier, France; <sup>14</sup>Université de Rennes 1, CHU Rennes Service de Cardiologie, Inserm LTSI U1099, Rennes, France; <sup>15</sup>Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau, Barcelona, Spain; <sup>16</sup>Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; <sup>17</sup>Structural Interventional Cardiology Division, Department of Clinical & Experimental Medicine, Careggi University Hospital, Florence, Italy; <sup>18</sup>Department of Cardiology, Institut Mutualiste Montsouris, Paris, France; <sup>19</sup>Cardiac Center, IKEM Prague, Prague, Czech Republic; <sup>20</sup>Department of Cardiology, Hospital Floridsdorf, Vienna, Austria; <sup>21</sup>Karl Landsteiner Institute for Cardiovascular and Critical Care Research Vienna, Vienna, Austria; <sup>22</sup>Instituto Cardiovascular, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; <sup>23</sup>Medical Department III, Heart Center Trier, Krankenhaus der Barmherzigen Brüder, Trier, Germany; <sup>24</sup>Heart Diseases Institute, Bellvitge University Hospital—IDIBELL, University of Barcelona, Barcelona, Spain; <sup>25</sup>Department of Internal Medicine 3/Cardiology, University Hospital St. Pölten, St. Pölten, Austria; <sup>26</sup>Struttura Complessa di Cardiologia, Ospedale Mauriziano, Torino, Italy; <sup>27</sup>Cardiology, Besancon Regional University Hospital Center, Besancon, France; <sup>28</sup>Cardiology, Polyclinique Du Bois, Lille, France; <sup>29</sup>Internal Medicine III, Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital of Saarland, Homburg, Germany; <sup>30</sup>Cardiology, Centro Cardiologico Monzino, Milan, Italy; <sup>31</sup>Department of Cardiology and Pulmonology, Georg-August-University, Göttingen, Germany; <sup>32</sup>Department of Cardiology, University Medicine Göttingen, Heart Center, Göttingen, Germany; <sup>33</sup>Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany; <sup>34</sup>Department of Medicine III, University of Heidelberg, German Centre for Cardiovascular Research (DZHK), Heidelberg, Germany; <sup>35</sup>Department of Interventional Cardiology, Hôpital Saint Joseph, Marseille, France; <sup>36</sup>Department de Cardiologie, Hôpital de Pitié-Salpêtrière AP-HP, Paris, France; <sup>37</sup>Department for Cardiovascular Surgery, Artemed Klinikum München, München, Germany; <sup>38</sup>Division of Cardiology, Department of Cardiovascular Surgery, L'Ospedale S.Giuseppe Moscati di Avellino, Avellino, Italy; <sup>39</sup>Department of Cardiothoracic Surgery, Heart Center, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany; <sup>40</sup>Cardiology Department, University Hospital Son Espases, Palma de Mallorca, Spain; <sup>41</sup>Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany; <sup>42</sup>Edwards Lifesciences, Prague, Czech Republic; and <sup>43</sup>Edwards Lifesciences, Nyon, Switzerland

Received 18 July 2023; revised 23 January 2024; accepted 27 February 2024

## Abstract

### Background and Aims

There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries.

\* Corresponding author. Tel: +49 431 500 22801, Email: [derk.frank@uksh.de](mailto:derk.frank@uksh.de)

† Deceased on December 15<sup>th</sup>, 2023

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

## Methods

This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety.

## Results

Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from  $7.7 \pm 7.0$  to  $5.8 \pm 5.6$  days (median 6 vs. 4 days;  $P < .001$ ). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days;  $P < .001$ ). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%;  $P < .001$ ) and decreased procedure (median 47 vs. 60 min;  $P < .001$ ) and intervention times (85 vs. 95 min;  $P < .001$ ). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%).

## Conclusions

Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.

## Structured Graphical Abstract

### Key Question


Does the implementation of 8 tailored BENCHMARK best practices lead to reduced hospital length of stay (LoS) and duration of intensive care stay in TAVI patients without compromising safety?

### Key Finding

BENCHMARK best practices were widely implemented and significantly reduced hospital LoS by 2 days and reduced LoS in the critical care units from 1.8 to 1.3 days without compromising patient safety.

### Take Home Message

A wider implementation of BENCHMARK best practices will make TAVI pathway more cost effective without impacting patient safety.



BENCHMARK: streamlined transcatheter aortic valve implantation (TAVI) pathway with retained safety. CCU, coronary care unit; ICU, intensive care unit; GW, general ward; IMC, intermediate care; PPM, permanent pacemaker. \*Includes patients with available data on LoS only.

## Keywords

Aortic stenosis • Quality of care • Prospective registry • Transcatheter aortic valve implantation • TAVI • Clinical care • Health services

## Introduction

Transcatheter aortic valve implantation (TAVI) is increasingly used for treating patients with severe symptomatic aortic stenosis (AS) irrespective of risk profile. With its wider adoption, there is an increasing need for streamlined patient pathways to improve efficient patient work-up, treatment, and early discharge without compromising patient safety.

Multiple studies have described factors associated with the potential for early and safe discharge after TAVI, including specific patient characteristics, minimalist peri-procedure approaches, the absence of post-procedural complications such as acute kidney injury (AKI) and conduction disturbances, and early ambulation.<sup>1–9</sup> The multicentre *Vancouver 3M (multidisciplinary, multimodality, but minimalist) TAVR study*<sup>10</sup> demonstrated the feasibility and safety of a clinical pathway inclusive of same-day admission for a procedure performed in a cardiac catheterization laboratory or hybrid operating room, local anaesthesia only or with conscious sedation, percutaneous access and closure, removal of a temporary pacemaker at the end of the intervention, standardized post-procedure care with early mobilization, and next-day discharge home.<sup>11</sup> Study findings confirmed and resulted in excellent safety and efficacy outcomes at 30 days. In addition, cumulative 30-day costs were \$11 305/patient lower in the 3M TAVR cohort.<sup>12</sup> Further, the multicentre *European Feasibility and Safety of Early Discharge After Transfemoral TAVI (FAST-TAVI) registry* demonstrated that pre-specified risk criteria can be effectively used to identify patients in an all-comers collective suitable for safe early discharge and to identify others who may require a longer length of stay (LoS).<sup>13,14</sup> This led to the concept of a dedicated TAVI coordinator or TAVI nurse, a suggestion that has been widely adopted in North America and other international regions.<sup>11,15</sup> In a recent assessment (COORDINATE study), the implementation of a TAVI coordinator led to increase in patient satisfaction and improved discharge management without compromising patient safety at 30 days.<sup>16</sup>

This evidence informed the development of the BENCHMARK study to measure the impact of eight tailored BENCHMARK best practices on hospital LoS and duration of critical care and patient satisfaction without compromising patient safety.

## Methods

BENCHMARK (ClinicalTrials.gov Identifier: NCT04579445) is a multicentre, international study of patients with severe symptomatic AS undergoing TAVI at 28 centres across Europe including Austria, France, Germany, Italy, Czech Republic, Romania, and Spain between January 2020 and March 2023 (primary completion of the 30-day follow-up).<sup>17</sup> Each participating centre was required to establish a physician lead and non-physician TAVI coordinator. At baseline, 13 centres had such a function already established and all centres ( $n=28$ ) had it established with the implementation of BENCHMARK (named TAVI coordinator in 19 centres, study nurse in 5 centres, research assistant in 1 centre, and other non-physician staff in 3 centres). BENCHMARK was conducted according to the European Medical Device Regulations and International Organization for Standardization (ISO 14155:2020) and the Declaration of Helsinki. BENCHMARK was approved by the independent ethics review boards at each participating site, and all patients provided written informed consent.

## Patients

Consecutive patients with severe symptomatic AS who underwent transfemoral TAVI with a balloon-expandable valve were retrospectively enrolled prior to and prospectively after the introduction of the BENCHMARK best

practices. Valve choice was considered to be appropriate for two reasons: (i) Edwards Lifesciences, the maker of a balloon-expandable valve, agreed to provide funding, and the majority of evidence on streamlining of the patient pathway was generated using balloon-expandable valves. In reality, only SAPIEN 3 and SAPIEN 3 Ultra valves were used. (ii) A single valve type was considered to result in less variation with respect to patient outcomes, such as pacemaker rates, which may result in an outcome bias if unevenly distributed. Across all participating centres, the mean proportion of balloon-expandable valves was 59.4%. Patients were required to be 18 years and older and were scheduled for follow-up visits at 30 days and 12 months after the procedure. Patients undergoing valve-in-valve procedures, who were pregnant, or for whom key variables for the assessment were missing (only for patients prior to the implementation) were excluded.

## BENCHMARK best practices

A total of eight best practices were implemented<sup>17</sup>, which included (i) tailored education of patient and family, (ii) determination of an anticipated discharge date at admission based on pre-procedural risk stratification and scheduling of post-procedural diagnostics, (iii) echocardiographic or angiographic check at the end of the procedure to confirm vascular access closure and absence of peri-procedural complications, (iv) nurse-led early mobilization (mobilization of the patient with the help of a nurse done 4–6 h after the intervention in the absence of complications), (v) use of a decision tree to determine the need for new pacemaker implantation if required without increasing hospital stay, (vi) criteria-based discharge, (vii) daily visit by implanting physician and interaction with the rest of the team, and (viii) education and alignment of the internal team (medical, nursing, and paramedical).

Prior to the BENCHMARK Education Phase, each centre identified a defined leadership team (i.e. multidisciplinary heart team) and self-assessed their current alignment of hospital performance with the BENCHMARK best practices. In the Education Phase, centres underwent online education on the BENCHMARK best practices led by their dedicated faculty member. After that, each centre had a post-education call to define the action plan with a designated mentor. During the Implementation Phase consisting of a 2-month time window, each centre introduced the tailored best practices into their hospital routine. Follow-up calls were arranged between the BENCHMARK education team and each centre every 2 weeks to offer assistance with regard to implementation progress. A further follow-up call was held after 30% of the aimed patient number had been included to allow further action plan development in case not all BENCHMARK best practices were not implemented until then.

## Study objectives

The principal objective of BENCHMARK was to document whether the implementation of tailored BENCHMARK best practices into the patient pathway decreases the total hospital LoS and reduces duration of critical care stay [defined as intensive care unit (ICU), cardiac/coronary care unit (CCU), or intermediate care (IMC)]. Intensive care unit and CCU were considered units of intensified care when 24 h critical care or life support was required. When the unit was specialized to look after cardiac patients, the unit was classified as a CCU. A patient was considered to be an IMC patient if he/she was not a patient on a general ward nor a patient of the ICU/CCU. Secondary objectives included the assessment of procedural success and complications, patient safety at discharge and 30 days, and patient quality of life (QoL).

## Data collection

Collected data included physical assessments, medical history and symptoms, diagnostic procedures, electrocardiography (ECG), echocardiography (Echo), hospitalization and procedural duration, safety parameters, QoL measures, patient satisfaction surveys, as well as parameters on resource utilization. Frailty was assessed using comprehensive assessment

of cognition (The Mini Mental State Exam-2) and activities of daily living (The Katz Activities of Daily Living).<sup>18,19</sup> The depth of sedation was defined as follows: minimal (anxiolysis), moderate (sleepy and relaxed but can follow simple instructions if asked and may remember parts of the procedure; breathing should not be affected), and deep sedation (sleeping through most of the procedure and unlikely to have recall). Quality of life was assessed using the Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ).<sup>20</sup> Patients treated with BENCHMARK best practices were interrogated how they assessed different domains of their treatment using a tailored questionnaire. No data on the size of the implanted valve, contrast, and fluoroscopy/radiation dose were collected in an attempt to balance the size of the electronic case report form (eCRF) against the specific purpose of the study. Data were captured in an eCRF (Software for Trials Europe GmbH, Berlin, Germany) and checked for plausibility and completeness.

## Statistical analysis

All available patient data were analysed and missing data were not imputed. Continuous variables were presented as mean  $\pm$  standard deviation (SD) or median and interquartile ranges (IQR). The Kolmogorov–Smirnov test was used to test for normal distribution. Categorical variables were reported as frequencies and percentages. Comparisons were made using a *t*-test or

Mann–Whitney *U* test for continuous variables and Pearson's  $\chi^2$  or Fisher's exact test for categorical variables. The interaction tests were performed using univariate analysis of variance for continuous variables and logistic regression for categorical variables. Adjustments for differences in baseline characteristics were performed for the primary outcome using a linear regression model, and the significance of independent variables and their interactions was assessed using analysis of variance (ANOVA) with type III sum of squares. The effect size of continuous variables for adjustment was calculated using Cohen's *d*. A *P*-value of  $<.05$  was considered statistically significant. All analyses were performed using IBM SPSS Statistics version 29 (IBM, Armonk, NY, USA) or R Core Team (<https://www.R-project.org/>).

## Results

We included 897 patients treated prior to and 1491 patients treated after the implementation of the BENCHMARK best practices. Patient characteristics were consistent with a known older TAVI population (Table 1). The mean age of the total BENCHMARK population was  $79.9 \pm 6.8$  years, 39.4% were female, and 58.5% had New York Heart Association (NYHA) functional class III or IV with a mean EuroSCORE II of  $4.8 \pm 5.8\%$ . The baseline profile of patients documented prior to

**Table 1** Patient characteristics

|                                      | Prior to BENCHMARK |                                      | BENCHMARK |                                      | P-value |
|--------------------------------------|--------------------|--------------------------------------|-----------|--------------------------------------|---------|
|                                      | N                  | Mean $\pm$ SD, median (IQR) or n (%) | N         | Mean $\pm$ SD, median (IQR) or n (%) |         |
| Age (years)                          | 897                | 79.8 $\pm$ 6.6<br>81.0 (76.0; 84.0)  | 1490      | 79.9 $\pm$ 6.8<br>81.0 (76.0; 85.0)  | .902    |
| Female gender                        | 897                | 369 (41.1)                           | 1491      | 571 (38.3)                           | .152    |
| Body mass index (kg/m <sup>2</sup> ) | 893                | 27.9 $\pm$ 5.1<br>27.4 (24.5; 30.7)  | 1487      | 27.5 $\pm$ 4.9<br>27.0 (24.2; 30.1)  | .046    |
| Aortic valve-related symptoms        |                    |                                      |           |                                      |         |
| Dizziness with exertion              | 893                | 224 (25.1)                           | 1472      | 360 (24.5)                           | .732    |
| (Pre-)syncope                        | 893                | 80 (9.0)                             | 1472      | 163 (11.1)                           | .101    |
| NYHA class III or IV                 | 890                | 543 (61.0)                           | 1473      | 840 (57.0)                           | .057    |
| Angina CCS 3 or 4                    | 892                | 54 (6.1)                             | 1472      | 60 (4.1)                             | .030    |
| Risk scores and frailty              |                    |                                      |           |                                      |         |
| EuroSCORE II                         | 877                | 5.0 $\pm$ 4.8<br>3.5 (1.8; 5.9)      | 1448      | 4.7 $\pm$ 6.3<br>2.8 (1.7; 4.8)      | <.001   |
| Frailty, severe                      | 894                | 37 (4.1)                             | 1481      | 40 (2.7)                             | .055    |
| Impaired mobility                    | 890                | 123 (13.8)                           | 1451      | 174 (12.0)                           | .197    |
| Cognitive deficit                    | 894                | 38 (4.3)                             | 1481      | 50 (3.4)                             | .274    |
| Comorbidities                        |                    |                                      |           |                                      |         |
| Previous myocardial infarction       | 896                | 131 (14.6)                           | 1479      | 204 (13.8)                           | .574    |
| Peripheral artery disease            | 896                | 1545 (17.3)                          | 1479      | 204 (13.8)                           | .021    |
| Diabetes mellitus                    | 890                | 284 (31.9)                           | 1451      | 446 (30.7)                           | .552    |
| Pulmonary hypertension               | 808                | 52 (6.4)                             | 1304      | 96 (7.4)                             | .418    |
| Renal insufficiency                  | 896                | 238 (26.6)                           | 1481      | 372 (25.1)                           | .435    |
| Prior permanent pacemaker            | 895                | 75 (8.4)                             | 1482      | 102 (6.9)                            | .178    |

SD, standard deviation; IQR, interquartile range; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society.

**Table 2** Electrocardiogram and echocardiography at baseline

|  | Prior to BENCHMARK |                                      | BENCHMARK |                                      | P-value |
|--|--------------------|--------------------------------------|-----------|--------------------------------------|---------|
|  | N                  | Mean $\pm$ SD or n (%)               | N         | Mean $\pm$ SD or n (%)               |         |
| <b>Electrocardiogram (ECG)</b>                               |                    |                                      |           |                                      |         |
| Rhythm   | 873                |                                      | 1448      |                                      | .824    |
| Sinus rhythm   |                    | 643 (73.7)                           |           | 1071 (74.0)                          |         |
| Atrial fibrillation  |                    | 156 (17.9)                           |           | 268 (18.5)                           |         |
| Pacemaker rhythm   |                    | 63 (7.2)                             |           | 95 (6.6)                             |         |
| Other  |                    | 11 (1.3)                             |           | 14 (1.0)                             |         |
| AV block second or third degree                              | 864                | 12 (1.4)                             | 1445      | 15 (1.0)                             | .448    |
| Left bundle branch block                                     | 873                | 110 (12.6)                           | 1450      | 141 (9.7)                            | .031    |
| Right bundle branch block                                    | 873                | 97 (11.1)                            | 1450      | 171 (11.8)                           | .618    |
| <b>Echocardiography</b>                                      |                    |                                      |           |                                      |         |
| Left ventricular ejection fraction (LVEF) < 50%              | 862                | 157 (18.2)                           | 1462      | 245 (16.8)                           | .370    |
| Aortic regurgitation, mod/severe                             | 851                | 165 (19.4)                           | 1442      | 274 (19.0)                           | .820    |
| Aorto-ventricular mean pressure gradient                     | 827                | 45.5 $\pm$ 13.1<br>44.0 (39.0; 52.0) | 1382      | 46.1 $\pm$ 13.8<br>45.0 (39.0; 53.0) | .658    |
| Aorto-ventricular peak pressure gradient                     | 683                | 71.7 $\pm$ 18.6<br>71.0 (62.0; 81.0) | 1061      | 73.5 $\pm$ 20.6<br>72.0 (62.0; 84.0) | .244    |
| V <sub>max</sub>   | 644                | 4.2 $\pm$ 0.8<br>4.2 (4.0; 4.6)      | 1091      | 4.2 $\pm$ 0.8<br>4.2 (3.9; 4.6)      | .987    |
| Aortic valve area (cm <sup>2</sup> )                         | 714                | 0.76 $\pm$ 0.32<br>0.73 (0.60; 0.90) | 1181      | 0.77 $\pm$ 0.24<br>0.75 (0.62; 0.90) | .188    |
| Aortic valve area indexed (cm <sup>2</sup> /m <sup>2</sup> ) | 711                | 0.41 $\pm$ 0.17<br>0.39 (0.32; 0.46) | 1183      | 0.41 $\pm$ 0.14<br>0.40 (0.33; 0.47) | .276    |

SD, standard deviation.

and after BENCHMARK implementation was largely comparable. Patients documented prior to BENCHMARK implementation had a slightly higher body mass index (BMI; 27.9 vs. 27.5 kg/m<sup>2</sup>,  $P = .046$ ), higher EuroSCORE II (5.0 vs. 4.7%,  $P < .001$ ), and higher presence of angina CCS3 or 4 (6.1% vs. 4.1%,  $P = .030$ ) and peripheral artery disease (17.3% vs. 13.8%,  $P = .021$ ). Electrocardiogram and echocardiography-based criteria were mostly similar between groups (Table 2). In the total population, atrial fibrillation was present in 18.3%. Pacemaker implantation prior TAVI was present in 9.4% of patients. Pre-existing second-degree atrio-ventricular block was documented in 0.3%; 17.3% had a left ventricular ejection fraction below 50%, and the mean aorto-ventricular pressure gradient was 45.9 mmHg.

### Implementation of BENCHMARK best practices

The majority of centres had already adopted the echo-/angiographic check (79%), the daily visit of patient by implanter (69%), and anticipated discharge date planning (52%) at baseline (Figure 1). With the BENCHMARK practice implementation, 'criteria-based discharge' use increased by a factor of 4.2 (97% vs. 23% at baseline), 'early mobilization' by a factor of 3.5 (87% vs. 25%), 'education of patient and family' (96% vs. 48%) by a factor of 2.0, and the use of a 'pacemaker


decision tree' (99% vs. 50%) also by a factor of 2.0. BENCHMARK best practices whose use significantly increased in patients with a short LoS ( $\leq$ median) were tailored education of patient and family, determination of an anticipated discharge date, use of a decision tree to determine the need for new PPM, early mobilization, criteria-based discharge, and daily visit to patient by implanter (see [Supplementary data online, Table S1](#)).

### Principal objective: length of stay

The implementation of BENCHMARK best practices resulted in a reduction in the mean LoS (time from admission to discharge) by  $\sim 2$  days from  $7.7 \pm 7.0$  to  $5.8 \pm 5.6$  days (median 6 vs. 4 days;  $P < .001$ ) (Figure 2A). Both the time from admission to TAVI ( $P = .040$  based on median) and the time from TAVI to discharge ( $P < .001$  based on the median) were significantly reduced.

The total LoS across all critical care units decreased from 1.8 to 1.3 days (median 1.1 vs. 0.9 days;  $P < .001$ ). The mean time spent in the ICU was reduced from 0.6 to 0.4 days and the time in the CCU from 0.7 to 0.4 days (Figure 2B); 3.4 days prior to and 2.7 days post-BENCHMARK implementation were spent on the general ward. Overall, the mean LoS after the intervention was reduced from 5.2 to 4.0 days (median 4.2 vs. 3.0 days;  $P < .001$ ).

To further explore the effect of the BENCHMARK best practices on total LoS and LoS in ICU/CCU/IMC, we performed the analysis



**Figure 1** BENCHMARK best practices implementation rate. PPI, permanent pacemaker implantation

adjusting for baseline variables with a  $P$ -value of  $\leq .1$  - NYHA class III or IV, angina CCS 3 or 4, severe frailty, and peripheral artery disease; the effect sizes for EuroSCORE II, BMI, and aorto-ventricular peak pressure gradient were small (Cohen's  $d < 0.2$ ), so these variables were not included. After the adjustment, the reduction in both total LoS ( $P < .001$ ) and LoS in ICU/CCU/IMC ( $P < .001$ ) after the BENCHMARK implementation remained significant. The reduction in LoS (overall and in ICU, CCU, and IMC) was also observed in subgroups defined by patient gender (male/female) and age ( $>75/\leq 75$  years) (see [Supplementary data online, Table S2](#)). Similarly, the implementation of BENCHMARK best practices led to the highest reduction in LoS in the subgroup of patients with a lower EuroSCORE.

## Secondary objectives: procedural and 30-day outcomes

Implementation of the BENCHMARK best practices was associated with an increased use of local anaesthesia with or without conscious sedation (96.1 vs. 84.3%;  $P < .001$ ) and reduction in deep sedation (8.2% vs. 20.3%) ([Table 3](#)). A minimalist anaesthesia strategy was significantly associated with overall LoS ( $P = .031$ ) but had no effect on the LoS in critical care ( $P = .897$ ) (see [Supplementary data online, Table S3](#)). There were significant decreases in procedure time (vascular access puncture to sheath removal/closure: median 47 vs. 60 min;  $P < .001$ ) and intervention time (start of sedation to patient exit: median 85 vs. 95 min;  $P < .001$ ) following the implementation of change.

Procedural success was  $>99\%$  with no significant differences between groups. Bleeding rates decreased from 4.0% to 2.1% ( $P = .007$ ).

At discharge and at 30 days, there was no significant difference in safety outcomes between patient groups ([Table 4](#)). There was a lower rate of major vascular complications in patients after BENCHMARK practice implementation both at discharge (1.8% vs. 3.2%;  $P = .024$ ) and 30 days (2.0% vs. 3.9%;  $P = .007$ ). Similarly, the rates of permanent pacemaker implantation were lower after the implementation of

BENCHMARK best practices at discharge (13.2% vs. 17.3%,  $P = .007$ ) and at 30 days (14.0% vs. 19.1%,  $P = .001$ ). Valve-related symptoms or worsening heart failure requiring re-hospitalization after discharge were low with no significant differences between groups (1.1% vs. 1.5%,  $P = .405$ ).

The rates of all-cause mortality and valve-related hospitalization were not significantly different in subgroups defined by sex (male/female), age ( $>75/\leq 75$  years), and EuroSCORE II (low, intermediate, and high) (see [Supplementary data online, Table S4](#)).


## Secondary objectives: patients' quality of life and satisfaction

Quality of life was measured after the implementation of BENCHMARK practices, but not before. Patients reported an improvement of their QoL based on the TASQ questionnaire from hospital admission (median 73 points) to discharge (median 86 points) and at 30-day follow-up (median 93 points;  $P < .001$ ) ([Figure 3A](#)). The same pattern was observed on patients' self-reported physical symptoms, physical limitations, emotional impact, and social limitations subscales. Health expectations were unaffected.

Patients reported they were overall either satisfied or very satisfied with their treatment in more than 90% of all domains with the items 'respectful interaction' (95.5%), 'in-house care' (95.2%), 'hospital examinations' (95.0%), and 'explanation of doctors/other professionals' (94.2%) reaching the highest agreement ([Figure 3B](#)).

## Discussion

The results of the BENCHMARK study demonstrate that the incorporation of BENCHMARK best practices led to a significant decrease in LoS by  $> 25\%$  (or 2 days) and reduced use of critical care resources without compromising patient safety at hospital discharge and at 30-day follow-up ([Structured Graphical Abstract](#)).



**Figure 2** Results for the primary objective: hospital length of stay broken down into door to needle and needle to door (A) and length of ICU, CCU, IMC, and general ward stay (B). ICU, intensive care unit; CCU, coronary care unit; IMC, intermediate care; GW, general ward

### Hospital length of stay and use of critical care resources

The reduction of hospital LoS has both clinical and economic benefits. In the present study, we demonstrated a significant decrease in the total hospital LoS (admission to discharge) by 2 days after the implementation of the BENCHMARK best practices. Furthermore, the LoS from admission to TAVI, and TAVI to discharge, including ICU and CCU stay, was also significantly reduced.

The length of hospital stay in BENCHMARK in general was also reported to be shorter compared with the results of study from the West German Heart and Vascular Centre.<sup>21</sup> Although authors reported a reduction in the total length of stay after the implementation of a TAVI coordinator, the time from admission to implantation was 6 days compared with 1.9 days in our study, while the time from TAVI to discharge was 7 days, compared with 5.8 days reported in BENCHMARK. The Vancouver 3M TAVR study<sup>10</sup> reported that, based on the use of objective screening criteria as well as streamlined peri- and post-procedural management, the proportion of patients being safely discharged home the day after the intervention reached 80.1%, which is higher than in the

BENCHMARK data set. It is important to note, however, that BENCHMARK is an all-comer data set, whereas in the Vancouver 3M TAVR study, the number of enrolled patients ( $n = 411$ ) was much lower than the number of screened patients ( $n = 1400$ ). The French FAST TAVI II study,<sup>22</sup> which studied patients discharged within 3 days after the intervention as the primary endpoint, reported an increase in the rate of patients being discharged early (58.1 vs. 42.3%;  $P < .0001$ ) after introducing 10 distinct quality of care measures targeting logistic domains and the prevention of complications. The numbers compare well with the shortening of the post-procedural stay from 5.3 to 4.0 days (median 4 vs. 3 days;  $P < .001$ ) in the BENCHMARK study. Efficient discharge planning plays a critical role in identifying suitable candidates for a safe early discharge after TAVI. One of the BENCHMARK practices included an implementation of an early discharge decision protocol, which was adapted from the FAST-TAVI registry.<sup>14</sup> Pre-specified criteria were considered after TAVI to define a low-risk population for early discharge, including factors such as NYHA class  $\leq$  II, patients having complications on Day 0 to 1 but free of signs or symptoms on Day 3, independent mobilization and self-caring, as well as the absence of unresolved AKI type 3, paravalvular leakage, stroke/transient ischaemic attack (TIA), and



**Table 3** Procedural details and outcomes

|   | Prior to BENCHMARK |                       | BENCHMARK |                       | P-value |
|---|--------------------|-----------------------|-----------|-----------------------|---------|
|   | N                  | Median (IQR) or n (%) | N         | Median (IQR) or n (%) |         |
| <b>Local anaesthesia (LA) ± conscious sedation</b>                  | 896                | 755 (84.3)            | 1482      | 1424 (96.1)           | <.001   |
| LA w/o sedation/anxiolytic  |                    | 57 (7.6)              |           | 138 (9.7)             |         |
| LA + minimal sedation/anxiolytic                                    |                    | 336 (44.6)            |           | 616 (43.4)            |         |
| LA + moderate sedation  |                    | 208 (27.6)            |           | 550 (38.7)            |         |
| Deep sedation   |                    | 153 (20.3)            |           | 116 (8.2)             |         |
| <b>Implanted heart valve</b>  | 896                |                       | 1482      |                       | <.001   |
| SAPIEN 3  |                    | 607 (67.7)            |           | 827 (55.8)            |         |
| SAPIEN 3 Ultra  |                    | 289 (32.3)            |           | 653 (44.1)            |         |
| Other valves  |                    | 0                     |           | 2 (0.1)               |         |
| <b>Procedural information</b>                                       |                    |                       |           |                       |         |
| Total procedure time  | 817                | 60 (40.5; 84)         | 1391      | 47 (33; 70)           | <.001   |
| Intervention time   | 815                | 95 (60; 120)          | 1402      | 85 (55; 120)          | <.001   |
| <b>Procedural success</b>   | 892                | 887 (99.4)            | 1470      | 1456 (99.0)           | .301    |
| Absence of procedural mortality                                     | 894                | 894 (100)             | 1470      | 1467 (99.8)           | .177    |
| Correct positioning of single valve into proper anatomical location | 894                | 894 (100)             | 1470      | 1467 (99.8)           | .177    |
| Intended performance of valve                                       | 892                | 888 (99.6)            | 1470      | 1459 (99.3)           | .374    |
| Device malfunction  | 894                | 2 (0.2)               | 1470      | 1 (0.1)               | .303    |
| <b>Complications</b>  |                    |                       |           |                       |         |
| Procedure aborted before device introduced                          | 896                | 0                     | 1480      | 1 (0.1)               | 1.000   |
| Second valve needed   | 896                | 5 (0.6)               | 1481      | 7 (0.5)               | .776    |
| Permanent pacemaker implanted                                       | 895                | 69 (7.7)              | 1482      | 87 (5.9)              | .079    |
| Conversion to conventional surgery                                  | 881                | 6 (0.7)               | 1429      | 4 (0.3)               | .195    |
| Bleeding  | 891                | 36 (4.0)              | 1459      | 31 (2.1)              | .007    |

SD, standard deviation.

haemodynamic instability. The implementation of this protocol has shown that the majority of unselected patients undergoing TAVI can be safely discharged early after the intervention and approximately one-third of patients were discharged later due to logistical and not medical reasons.<sup>13</sup>

Due to the fact that a substantial number of patients in both phases in our registry was recruited during the COVID-19 pandemic period (pre-BENCHMARK, 2020–22; BENCHMARK, 2021–23), there was a certain impact of the pandemic which needs to be acknowledged. However, although one may expect a prolonged length of hospital stay, several studies have shown that the LoS in TAVI patients was either comparable or shorter during the COVID-19 pandemic compared with the pre-pandemic period.<sup>23–27</sup> Thus, we may only speculate that the pandemic itself had an effect on the TAVI LoS and outcomes in patients in either phase.

## Procedural and 30-day outcomes

Technical success at the exit from the procedure room was reported for 99% of the patients irrespective of the implementation of the BENCHMARK practices. The relevant reduction of procedural time is

noteworthy and potentially associated with a reduction of contrast amount and fluoroscopy/radiation dose, although no specific data were collected. Adverse outcomes at discharge and 30 days were low with a 30-day mortality of only 0.6% in the BENCHMARK group vs. 0.5% prior to its implementation. Furthermore, rates of stroke/TIA, life-threatening bleeding, stage II/III AKI, and coronary artery obstruction were all low. Importantly, no increase in the rate of hospital readmission was observed after BENCHMARK implementation, despite earlier discharge.

Similarly low complication rates at 30 days were reported in previous studies.<sup>16,21</sup> The Vancouver 3M TAVR study results also demonstrated that a streamlined patient pathway allowed for safe expedited discharge.<sup>10</sup> A composite primary endpoint of all-cause mortality or stroke by 30 days occurred in 2.9% of the patients (vs. 2.0% in our data set). Major vascular complications were reported by 2.4% (vs. 2.0% BENCHMARK), readmissions by 9.2% (vs. 5.3% BENCHMARK), and cardiac readmissions by 5.7% (vs. 1.1% BENCHMARK). The results are also in line with previous reports from the FAST-TAVI study, which investigated the effects of close monitoring, early mobilization, accelerated reconditioning, and discharge planning on the appropriacy of early discharge. The study showed that patients appropriately discharged early

**Table 4** Outcomes in-hospital and at 30 days (cumulative)

|  | In-hospital        |            |           |            |         | 30-day follow-up   |            |           |            |         |
|--|--------------------|------------|-----------|------------|---------|--------------------|------------|-----------|------------|---------|
|  | Prior to BENCHMARK |            | BENCHMARK |            | P-value | Prior to BENCHMARK |            | BENCHMARK |            | P-value |
|  | N                  | n (%)      | N         | n (%)      |         | N                  | n (%)      | N         | n (%)      |         |
| All-cause mortality                                | 896                | 2 (0.2)    | 1460      | 7 (0.5)    | .497    | 816                | 4 (0.5)    | 1230      | 9 (0.6)    | .500    |
| TAVI related                                       |                    | 2          |           | 4          |         |                    | 2          |           | 4          |         |
| Cardiac, not TAVI related                          |                    | 0          |           | 3          |         |                    | 0          |           | 3          |         |
| Non-cardiac  |                    | 0          |           | 0          |         |                    | 2          |           | 2          |         |
| Stroke/TIA   | 895                | 7 (0.8)    | 1453      | 13 (0.9)   | .773    | 808                | 10 (1.2)   | 1311      | 18 (1.4)   | .791    |
| Life-threatening bleeding                          | 894                | 10 (1.1)   | 1453      | 13 (0.9)   | .593    | 809                | 11 (1.4)   | 1307      | 16 (1.2)   | .782    |
| AKI (stage 2/3, incl. dialysis)                    | 894                | 2 (0.2)    | 1453      | 9 (0.6)    | .173    | 808                | 4 (0.5)    | 1306      | 10 (0.8)   | .456    |
| Coronary artery obstruction requiring intervention | 895                | 3 (0.3)    | 1453      | 3 (0.2)    | .548    | 803                | 5 (0.6)    | 1305      | 5 (0.4)    | .443    |
| Major vascular complication                        | 895                | 29 (3.2)   | 1453      | 26 (1.8)   | .024    | 812                | 32 (3.9)   | 1308      | 26 (2.0)   | .007    |
| Permanent pacemaker                                | 897                | 155 (17.3) | 1473      | 195 (13.2) | .007    | 897                | 171 (19.1) | 1473      | 206 (14.0) | .001    |
| Re-hospitalization <sup>a</sup>                    |                    |            |           |            |         |                    |            |           |            |         |
| Valve-related symptoms or worsening CHF            |                    |            |           |            |         | 809                | 12 (1.5)   | 1305      | 14 (1.1)   | .405    |
| Other reasons                                      |                    |            |           |            |         | 809                | 44 (5.4)   | 1305      | 55 (4.2)   | .195    |

TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack; AKI, acute kidney injury; CHF, congestive heart failure.

<sup>a</sup>Not applicable at discharge.

had very low rates of all-cause mortality, vascular complications (0.3%), permanent pacemaker implantation (4.3%), stroke (0.0%), and major bleeding at 30 days (0.3%).<sup>13,14</sup> The French FAST TAVI II study<sup>22</sup> reported a 30-day mortality of 1.0% for the control and 0.5% for the intervention arms, which was not statistically different ( $P = .29$ ) and in a similar order than the mortality in BENCHMARK. Especially the early mobilization of patients after the intervention could be implemented more decisively as rates were on the lower end in BENCHMARK even after the introduction of the best practices.

BENCHMARK was associated with a reduction of clinically relevant bleeding, and the peri-procedural rate was 4.0% prior to BENCHMARK and 2.1% with the implementation of BENCHMARK ( $P = .007$ ). Procedural factors and antithrombotic management may also contribute to individual bleeding susceptibility. There is a six-item score (PREDICT-TAVR) which includes blood haemoglobin, serum iron, creatinine clearance, common femoral artery diameter, and dual antiplatelet as well as anticoagulant therapy.<sup>28</sup> Unfortunately, none of these variables were captured in BENCHMARK.

Major vascular complications were noted in 3.2% and 1.8% of patients up until discharge ( $P = .024$ ) and 3.9% vs. 2.0% at 30 days ( $P = .007$ ). Major vascular complications were defined as (i) aortic dissection or aortic rupture; (ii) vascular (arterial or venous) injury (perforation, rupture, dissection, stenosis, ischaemia, arterial or venous thrombosis including pulmonary embolism, arteriovenous fistula, pseudoaneurysm, haematoma, retroperitoneal haematoma, infection) or compartment syndrome resulting in death, VARC type  $\geq 2$  bleeding, limb or visceral ischaemia, or irreversible neurologic impairment; (iii) distal embolization (non-cerebral) from a vascular source resulting


in death, amputation, limb or visceral ischaemia, or irreversible end-organ damage; (iv) unplanned endovascular or surgical intervention resulting in death, VARC type  $\geq 2$  bleeding, limb or visceral ischaemia, or irreversible neurologic impairment; and (v) closure device failure resulting in death, VARC type  $\geq 2$  bleeding, limb or visceral ischaemia, or irreversible neurologic impairment.<sup>29</sup> As such, while vascular access bleeding was already prevented by high implementation rates of angiographic check of closure, there are more potential sources which may have led to a reduction of major vascular complications.

Our study provides importance evidence that the eight BENCHMARK best practices can be implemented successfully in diverse clinical contexts without compromising the safety of patients.

## Patients' quality of life and satisfaction

Improved QoL is one of the major treatment goals in patients with severe aortic stenosis. With the implementation of BENCHMARK practices, patients reported improved QoL at 30 days compared with baseline, with early improvements seen already at discharge. These findings are in line with previous studies that demonstrated substantial early QoL improvements after TAVI.<sup>30–33</sup> Despite the fact that patients in our study were old and the majority presented with severe symptoms, large improvement in health status and QoL in most patients was still observed after the intervention. Unfortunately, we had no opportunity to collect QoL data prior to the BENCHMARK programme implementation.

BENCHMARK was associated with high patient satisfaction with most patients reporting feeling satisfied or very satisfied with their patient journey. One of the highest satisfaction domains included the explanations



**Figure 3** Improvement in quality of life based on TASQ (A) and patient satisfaction with the BENCHMARK approach (B). TASQ, Toronto Aortic Stenosis Questionnaire; FU, follow-up

regarding the treatment and care and a respectful treatment from the health professionals. This reflects the fact that patients were well informed and prepared for the procedure and post-procedure care, improving their self-reliance, self-efficacy, and active involvement in health-related decisions. Similar findings were reported from the COORDINATE study with high patient satisfaction with the treatment pathway after the introduction of a TAVI coordinator.<sup>16</sup> Therefore, TAVI coordinators play an essential role in patient education as well as enhanced communication between the heart team and patient and their family.

## Perspectives

The BENCHMARK programme is a multidisciplinary quality improvement project facilitated by peer-to-peer mentorship and the translation

of contemporary evidence. The way it is designed today improves the patient pathway in the hospital and what the hospital and its staff may be able to do to streamline the patient pathway and make it more effective while retaining the safety of TAVI. It appears reasonable to enter into a discussion how the BENCHMARK pathway may be further improved.

A potential further objective of such programmes is to further reduce the hospital LoS. Same-day admission and discharge are potentially feasible if patients experience no complications and do not have an increased risk of pacemaker requirements.<sup>34</sup> While it appears possible in some European countries, there is a reimbursement barrier in others. For example, in Germany, there is a reimbursement for TAVI that assumes a minimum LoS after the procedure. Compared with other countries in the BENCHMARK data set and beyond (USA,

Canada, Australia), the hospital stay in Germany is long, but if patients are discharged early in Germany, the hospital may partially lose its full reimbursement. Therefore, from an economic perspective of the hospital, early discharge is of limited value. These hurdles need to be overcome to result in a truly efficient patient pathway for TAVI. Although the economic benefits of shortened inpatient stays and reduced need for intensive bed capacity have not been directly assessed in our study, such analysis is currently being planned.

Finally, going beyond the hospitalization for the procedure, the definition of an AS pathway may be potentially expanded.<sup>35</sup> The time from diagnosis to referral and from referral to the actual intervention is still very long in some European countries and can certainly be improved in all of them.

## Limitations

While the multinational nature of this study increases the applicability of the findings, the existing inter- and intra-country differences in patient management and treatment need to be considered. Due to the lack of randomization, there is a potential for confounding and bias in the analysis with limited ability for adjustment. Although patients were compared before and after the implementation of the BENCHMARK best practices, the prior patient data were collected retrospectively, which may have introduced bias due to missing data. In addition, QoL, patient satisfaction, and staff working hours were not documented prior to the implementation of the BENCHMARK practices, limiting the assessment of improvements. Lastly, the time window of the study was quite short, making it unlikely that relevant changes in centre proficiency occurred while the study was ongoing. However, we cannot rule out that the study results could be partly attributable to other factors, independently of implementation of the BENCHMARK practices.

## Conclusion

Our findings suggest that the introduction of the BENCHMARK best practices led to a streamlined TAVI patient pathway and reduced procedure time and length of hospital stay, while the overall patient safety at 30 days did not appear to be compromised. As TAVI expands to all severe AS patients, regardless of surgical risk, a wider implementation of the BENCHMARK practices appears warranted and would reduce procedure-related and resource utilization costs as well as other risks associated with prolonged hospitalization.

## Acknowledgements

The authors thank all centres participating in this study.

## Supplementary data

Supplementary data are available at *European Heart Journal* online.

## Declarations

### Disclosure of Interest

D.F. received support for the present manuscript, payment for lectures/presentations, and support for attending meetings from Edwards Lifesciences. E.D. received consulting fees from Edwards Lifesciences. S.L. received consulting fees and support for attending meetings from

Edwards Lifesciences and Medtronic. D.F.M. received support for the present manuscript, consulting fees, payment for lectures/presentations, and support for attending meetings from Edwards Lifesciences. D.F. received consulting fees from Edwards Lifesciences. F.S. received payment for lectures/presentations from Edwards Lifesciences, Medtronic, and Abbott and is on the Data Safety Monitoring Board/Advisory Board of Edwards Lifesciences. C.A.U.-C. received consulting fees from Edwards Lifesciences and payment for lectures/presentations from Medtronic and Biotronik and is on the Data Safety Monitoring Board/Advisory Board of Medtronic. C.S.E. received consulting fees from Medtronic, Edwards Lifesciences, and Abbott. V.A. received consulting fees from Boston Scientific and payment for lectures/presentations from Edwards Lifesciences, Medtronic, and Abbott. L.A. received speaker fees from Edwards Lifesciences. Ji.M. received grants, consulting fees, and payment/honoraria for lectures/presentations from Edwards Lifesciences, payment for lectures/presentations from St. Jude Medical Coordination Center BVBA (Abbott), and stock on Leviticus Cardio Ltd. A.S. received grant from Edwards Lifesciences. L.N.-F. received consulting fees from Edwards Lifesciences and Abbott Vascular. N.W. received grant from Shockwave Medical and Abiomed and support for attending meetings from Edwards Lifesciences, Medtronic, and Boston and is on the Data Safety Monitoring Board/Advisory Board of the Cingular Study. Ju.M. received grants and support for attending meetings from Boston Scientific, Medtronic, and Edwards Lifesciences, grant from Abbott, and payment for lectures/presentations from Edwards Lifesciences and AOP, is on the Data Safety Monitoring Board/Advisory Board of Amgen, and is an European Society of Cardiology Nominating Committee Member 2022–24. N.M. received support for the present manuscript and consulting fees from Edwards Lifesciences; consulting fees from Abbott, Terumo, and BMS; and payment for lectures/presentations from AstraZeneca, Bayer, and Servier. F.M. received grants from Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Herzstiftung, Ablative Solutions, Medtronic, and ReCor Medical and consulting fees and payment for lectures/presentations from Ablative Solutions, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor Medical, Servier, and Terumo. T.S. received support for the present manuscript from Edwards Lifesciences; consulting fees from Bristol Myers Squibb; payment for lectures/presentations from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Corvia, Edwards Lifesciences, Medtronic, Myocardia, Novartis, and Pfizer; and support for attending meetings from Teleflex, Corvia, Edwards Lifesciences, Abbott, and Medtronic and is on the Data Safety Monitoring Board/Advisory Board of Bristol Myers Squibb. Flori.L. received grant from Edwards Lifesciences and payment for lectures from Edwards Lifesciences and Medtronic. J.P.C. received grants from Medtronic, BMS (speaker fees), AstraZeneca (speaker fees), and Abbott. P.B. is representing the sponsor IPPMed who received funding from Edwards Lifesciences for performing the study. V.H. and C.M.L. are employees of IPPMed. J.K., W.W., and R.R. are employees of Edwards Lifesciences. Ge.M. received honoraria for consultancy for the present manuscript, educational grant, consulting fees, and payment for lectures/presentations from Edwards Lifesciences and is now an employee of Edwards Lifesciences. All other authors represent centres who received compensation from Edwards Lifesciences for the documentation of patients.

## Data Availability

Available from the corresponding author upon reasonable request.

## Funding

The study is funded by Edwards Lifesciences and performed under the sponsorship of IPPMed—Institute for Pharmacology and Preventive Medicine GmbH, Cloppenburg, Germany.

## Ethical Approval

BENCHMARK was approved by the independent ethics review boards at each participating site, and all patients provided written informed consent.

## Pre-registered Clinical Trial Number

ClinicalTrials Identifier: NCT04579445.

## Appendix

### BENCHMARK Investigator Group

#### Principal Investigators

Derk Frank (Kiel, Germany)  
Gemma McCalmont (Middlesbrough, UK)

#### Sponsor Representative and Project Management

Peter Bramlage (Cloppenburg, Germany)  
Claudia M. Lüske (Cloppenburg, Germany)  
Marie Zielinski (Cloppenburg, Germany)  
Daniel Greinert (Cloppenburg, Germany)  
Cornelia Deutsch (Cloppenburg, Germany)  
Violetta Hachaturyan (Cloppenburg, Germany)

#### Steering Committee

Eric Durand (Rouen, France)  
Sandra Lauck (Vancouver, BC, Canada)  
Douglas Muir (Middlesbrough, UK)  
Mark Spence (Dublin, Ireland)  
Mariuca Vasa-Nicotera (Sindelfingen, Germany)  
David Wood (Vancouver, BC, Canada)  
Francesco Saia (Bologna, Italy)

#### Funder Representatives

Jana Kurucova (Prague, Czech Republic)  
Wilbert Wesselink (Prague, Czech Republic)  
Radka Rakova (Prague, Czech Republic)  
Martin Thoenes (Geneva, Switzerland)

#### Investigators/Centres

Cristóbal A. Urbano-Carrillo, Carlos Lara García, Beatriz Chamorro (Malaga, Spain)  
Damien Bouchayer, Jean-Philippe Claudel, Hervé Perrier, Viktoria Frebault (Lyon, France)  
Vlad Anton Iliescu, Catalina Andreea Parasca (Bucharest, Romania)  
Christophe Saint Etienne, Katia Lassouani (Tours, France)  
Florence Leclercq, Wassim Zitouni, Sonia Soltani (Montpellier, France)  
Vincent Auffret, Rosalie Le Gal (Rennes, France)  
Lluís Asmarats, Elena Jimenez Xarrie (Barcelona, Spain)  
Carlo Di Mario, Niccolò Ciardetti, Francesco Meucci (Florence, Italy)  
Aurelie Veugeois, Imane Bagdadi (Paris, France)  
Jiri Maly, Lenka Kolinova (Prague, Czech Republic)  
Andreas Schober, Georg Delle-Karth, Claudia Schuster, Marie-Christine Leitgeb (Vienna, Austria)  
Luís Nombela-Franco, Esther Bernardo García, María Aránzazu Ortega Pozzi (Madrid, Spain)  
Nikos Werner, Jürgen Leick, Michael Lauterbach, Hannah Waschbüsch (Trier, Germany)

Joan Antoni Gómez-Hospital, Guillem Muntané (Barcelona, Spain)  
Julia Mascherbauer Olga Daxböck, Mirela Butkovic, Simona Popescu (St. Pölten, Austria)  
Giuseppe Musumeci, Martina Perrero (Turin, Italy)  
Nicolas Meneveau, Stephanie Watbled (Besancon, France)  
Thibaud Meurice, Maxence Delomez (Lille, France)  
Felix Mahfoud, Bruno Scheller, Sebastian Ewen, Ann-Kathrin Berger, Christina Koch, Alexandra Engel (Homburg, Germany)  
Federico De Marco, Paolo Olivares (Milan, Italy)  
Tim Seidler, Frieder Wolf, Carolin Müller, Maren Hünermund (Göttingen, Germany)  
Florian Leuschner, Mathias Konstandin, Lisa Linz, Hannah Ulbricht (Heidelberg, Germany)  
Patrick Joly, Sabrina Siame (Marseille, France)  
Jean-Philippe Collet, Nassima Ait Amrane (Pitie Salpetriere, Paris, France)  
Ferdinand Vogt, Dow Rosenzweig (Munich, Germany)  
Emilio Di Lorenzo, Barbara Cefalo (Avellino, Italy)  
Elmar Kuhn, Vera Wolf (Cologne, Germany)  
Vicente Peral Disdier, Jaume Maristany Daunert, Maria Carmen de la Bandera Sanchez (Mallorca, Spain)

## References

- Vendrik J, Vlastra W, van Mourik MS, Delewi R, Beijk MA, Lemkes J, et al. Early mobilisation after transfemoral transcatheter aortic valve implantation: results of the MobiTAVI trial. *Neth Heart J* 2020;**28**:240–8. <https://doi.org/10.1007/s12471-020-01374-5>
- Lauck SB, Wood DA, Baumbusch J, Kwon JY, Stub D, Achtem L, et al. Vancouver transcatheter aortic valve replacement clinical pathway: minimalist approach, standardized care, and discharge criteria to reduce length of stay. *Circ Cardiovasc Qual Outcomes* 2016;**9**:312–21. <https://doi.org/10.1161/CIRCOUTCOMES.115.002541>
- Barbanti M, Capranzano P, Ohno Y, Attizzani GF, Gulino S, Imme S, et al. Early discharge after transfemoral transcatheter aortic valve implantation. *Heart* 2015;**101**:1485–90. <https://doi.org/10.1136/heartjnl-2014-307351>
- Aldalati O, Keshavarzi F, Kaura A, Byrne J, Eskandari M, Deshpande R, et al. Factors associated with safe early discharge after transcatheter aortic valve implantation. *Cardiol J* 2018;**25**:14–23. <https://doi.org/10.5603/Cj.a2017.0087>
- Alkhalil A, Lamba H, Deo S, Bezerra HG, Patel SM, Markowitz A, et al. Safety of shorter length of hospital stay for patients undergoing minimalist transcatheter aortic valve replacement. *Catheter Cardiovasc Interv* 2018;**91**:345–53. <https://doi.org/10.1002/ccd.27230>
- Mallikethi-Reddy S, Akintoye E, Telila T, Sudhakar R, Jagadeesh K, Briassoulis A, et al. Transcatheter aortic valve implantation in the United States: predictors of early hospital discharge. *J Interv Cardiol* 2017;**30**:149–55. <https://doi.org/10.1111/joic.12373>
- Kamioka N, Wells J, Keegan P, Lerakis S, Binongo J, Corrigan F, et al. Predictors and clinical outcomes of next-day discharge after minimalist transfemoral transcatheter aortic valve replacement. *JACC Cardiovasc Interv* 2018;**11**:107–15. <https://doi.org/10.1016/j.jcin.2017.10.021>
- Durand E, Eltchaninoff H, Canville A, Bouhazam N, Godin M, Tron C, et al. Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation with the Edwards SAPIEN-XT prosthesis. *Am J Cardiol* 2015;**115**:1116–22. <https://doi.org/10.1016/j.amjcard.2015.01.546>
- Serletis-Bizios A, Durand E, Cellier G, Tron C, Bauer F, Glinel B, et al. A prospective analysis of early discharge after transfemoral transcatheter aortic valve implantation. *Am J Cardiol* 2016;**118**:866–72. <https://doi.org/10.1016/j.amjcard.2016.06.035>
- Wood DA, Lauck SB, Cairns JA, Humphries KH, Cook R, Welsh R, et al. The Vancouver 3 M (multidisciplinary, multimodality, but minimalist) clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: the 3 M TAVR study. *JACC Cardiovasc Interv* 2019;**12**:459–69. <https://doi.org/10.1016/j.jcin.2018.12.020>
- Lauck SB, Sathananthan J, Park J, Achtem L, Smith A, Keegan P, et al. Post-procedure protocol to facilitate next-day discharge: results of the multidisciplinary, multimodality but minimalist TAVR study. *Catheter Cardiovasc Interv* 2020;**96**:450–8. <https://doi.org/10.1002/ccd.28617>
- Butala NM, Wood DA, Li H, Chinnakondepalli K, Lauck SB, Sathananthan J, et al. Economics of minimalist transcatheter aortic valve replacement: results from the 3M-TAVR economic study. *Circ Cardiovasc Interv* 2022;**15**:e012168. <https://doi.org/10.1161/CIRCINTERVENTIONS.122.012168>
- Barbanti M, van Mourik MS, Spence MS, Iacovelli F, Martinelli GL, Muir DF, et al. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. *EuroIntervention* 2019;**15**:147–54. <https://doi.org/10.4244/EIJ-D-18-01197>

14. Barbanti M, Baan J, Spence MS, Iacovelli F, Martinelli GL, Saia F, et al. Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation—rationale and design of the FAST-TAVI registry. *BMC Cardiovasc Disord* 2017;**17**:259. <https://doi.org/10.1186/s12872-017-0693-0>
15. Lauck S, Forman J, Borregaard B, Sathananthan J, Achten L, McCalmont G, et al. Facilitating transcatheter aortic valve implantation in the era of COVID-19: recommendations for programmes. *Eur J Cardiovasc Nurs* 2020;**19**:537–44. <https://doi.org/10.1177/1474515120934057>
16. Bohmann K, Burgdorf C, Zeus T, Joner M, Alvarez H, Berning KL, et al. The COORDINATE pilot study: impact of a transcatheter aortic valve coordinator program on hospital and patient outcomes. *J Clin Med* 2022;**11**:1205. <https://doi.org/10.3390/jcm11051205>
17. McCalmont G, Durand E, Lauck S, Muir DF, Spence MS, Vasa-Nicotera M, et al. Setting a benchmark for resource utilization and quality of care in patients undergoing transcatheter aortic valve implantation in Europe—rationale and design of the international BENCHMARK registry. *Clin Cardiol* 2021;**44**:1344–53. <https://doi.org/10.1002/clc.23711>
18. Katz S, Ford AB, Moskowitz RV, Jackson BA, Jaffe MV. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. *JAMA* 1963;**185**:914–9. <https://doi.org/10.1001/jama.1963.03060120024016>
19. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;**12**:189–98. [https://doi.org/10.1016/0022-3956\(75\)90026-6](https://doi.org/10.1016/0022-3956(75)90026-6)
20. Frank D, Kennon S, Bonaros N, Stastny L, Romano M, Lefevre T, et al. Aortic valve replacement: validation of the Toronto Aortic Stenosis Quality of Life Questionnaire. *ESC Heart Fail* 2021;**8**:270–9. <https://doi.org/10.1002/ehf2.12961>
21. Lortz J, Lortz TP, Johannsen L, Rammos C, Steinmetz M, Lind A, et al. Clinical process optimization of transfemoral transcatheter aortic valve implantation. *Future Cardiol* 2021;**17**:321–7. <https://doi.org/10.2217/fca-2020-0010>
22. Durand E, Beziau-Gasnier D, Michel M, Iung B, Tchetché D, Bonnet G, et al. Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial. *Eur Heart J* 2024;ehae081. <https://doi.org/10.1093/eurheartj/ehae081>
23. Reddavid C, Costa G, Valvo R, Criscione E, Strazzieri O, Motta S, et al. Transcatheter aortic valve implantation during COVID-19 pandemic: an optimized model to relieve healthcare system overload. *Int J Cardiol* 2022;**352**:190–4. <https://doi.org/10.1016/j.ijcard.2022.01.038>
24. Valdebenito M, Massalha E, Barbash IM, Maor E, Fefer P, Guetta V, et al. Transcatheter aortic valve implantation during the COVID-19 pandemic. *Am J Cardiol* 2021;**145**: 97–101. <https://doi.org/10.1016/j.amjcard.2020.12.086>
25. Tan J, Teoh TK, Ivanova J, Jadhav S, Varcocoe R, Baig K, et al. The impact of the COVID-19 pandemic on transcatheter aortic valve implantation (TAVI) services in the United Kingdom: a tertiary centre experience. *Heart* 2021;**107**:A13–4. <https://doi.org/10.1136/heartjnl-2021-BCS.17>
26. Ryffel C, Alaour B, Tomii D, Okuno T, Temperi F, Bruno J, et al. Impact of COVID-19 surge periods on clinical outcomes of transcatheter aortic valve implantation. *Am J Cardiol* 2023;**204**:32–9. <https://doi.org/10.1016/j.amjcard.2023.07.072>
27. Joseph J, Kotronias RA, Estrin-Serluis T, Cahill TJ, Kharbanda RK, Newton JD, et al. Safety and operational efficiency of restructuring and redeploying a transcatheter aortic valve replacement service during the COVID-19 pandemic: the Oxford experience. *Cardiovasc Revasc Med* 2021;**31**:26–31. <https://doi.org/10.1016/j.carrev.2020.12.002>
28. Avvedimento M, Real C, Nuche J, Farjat-Pasos J, Galhardo A, Trinh KH, et al. Incidence, predictors, and prognostic impact of bleeding events after TAVR according to VARC-3 criteria. *JACC Cardiovasc Interv* 2023;**16**:2262–74. <https://doi.org/10.1016/j.jcin.2023.07.005>
29. Généreux P, Piazza N, Alu Maria C, Nazif T, Hahn Rebecca T, Pibarot P, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. *J Am Coll Cardiol* 2021;**77**:2717–46. <https://doi.org/10.1016/j.jacc.2021.02.038>
30. Lauck SB, Arnold SV, Borregaard B, Sathananthan J, Humphries KH, Baron SJ, et al. Very early changes in quality of life after transcatheter aortic valve replacement: results from the 3 M TAVR trial. *Cardiovasc Revasc Med* 2020;**21**:1573–8. <https://doi.org/10.1016/j.carrev.2020.05.044>
31. Arnold SV, Spertus JA, Vemulapalli S, Li Z, Matsouka RA, Baron SJ, et al. Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: a report from the STS/ACC Transcatheter Valve Therapy Registry. *JAMA Cardiol* 2017;**2**:409–16. <https://doi.org/10.1001/jamacardio.2016.5302>
32. Bona V, Khawaja MZ, Bapat V, Young C, Hancock J, Redwood S, et al. Early and late changes in quality of life following transcatheter aortic valve implantation using the transfemoral and transapical approaches. *EuroIntervention* 2015;**11**:221–9. <https://doi.org/10.4244/EIJV1112A41>
33. Lauck SB, Yu M, Ding L, Hardiman S, Wong D, Sathananthan J, et al. Quality-of-life outcomes after transcatheter aortic valve implantation in a “real world” population: insights from a prospective Canadian database. *CJC Open* 2021;**3**:1033–42. <https://doi.org/10.1016/j.cjco.2021.04.006>
34. Krishnaswamy A, Kaur S, Isogai T, Zhou L, Shekhar S, Yun J, et al. Minimalist mitral valve-in-valve replacement using conscious sedation and intracardiac echocardiography is feasible and safe. *JACC Cardiovasc Interv* 2022;**15**:1288–90. <https://doi.org/10.1016/j.jcin.2022.03.022>
35. Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, et al. Facilitated data relay and effects on treatment of severe aortic stenosis in Europe. *J Am Heart Assoc* 2019;**8**:e013160. <https://doi.org/10.1161/JAHA.119.013160>